Buy the Dip Monday: 66% ROIC at 88% Off and Pharma Insiders Adding Into Approvals

This Week's Setup

Earnings yields range from 5.9% to 15.4% across eight names while the S&P 500 CAPE sits at 38.9, compressing the opportunity set into companies trading materially below the long-cycle average.

Fear & Greed at 40 reflects anxiety around macro positioning, yet four tickers print ROIC above 16% and six hold drawdowns deeper than 20%.

Insiders deployed capital across three names in the past month, with pharma executives adding shares into approval cycles and operational milestones.

Quick Scan

The 8 Names

1. American Eagle Outfitters, Inc. (AEO)

P/E: 12.0 | Earnings yield: 8.4% | 52w drawdown: -33.2%

The company trades at 11.97× earnings with a 6.1% free cash flow yield and 7.5% ROIC, a profile that historically suggests operational stability despite the 33% price decline. Gross margin of 36.5% and 4.1% year-over-year revenue growth frame a business navigating category headwinds without breaking.

Insiders sold 1.1 million net shares over six months with zero buy transactions, signaling management conviction that does not align with the valuation. Debt-to-equity at 1.11 constrains capital allocation flexibility in a retail environment where inventory turns dictate margin defense.

Short interest at 8.8% of float sits above the screen average, reflecting betting that the turnaround narrative will not materialize quickly enough to reverse the drawdown momentum.

2. EQT Corporation (EQT)

P/E: 9.8 | Earnings yield: 10.2% | 52w drawdown: -24.5%

Revenue growth of 60% year-over-year combines with 9.2% ROIC and an 8.8% free cash flow yield while the stock trades at 9.78× earnings, a setup where operational acceleration meets valuation dislocation. EV-to-EBITDA at 5.73 and debt-to-equity at 0.25 frame one of the cleanest balance sheets in the energy names on this screen.

CEO Toby Rice added shares on June 9, deploying capital into a 24% drawdown while analyst targets imply 36% upside to $70.04. Gross margin of 45.9% and a normalized 10-year P/E of 17.8 suggest the current price compresses the valuation against long-cycle earning power.

Natural gas pricing volatility remains the single largest risk, with data-center-driven demand forecasts vulnerable to infrastructure build-out delays and alternative energy substitution.

3. VanEck Gold Miners ETF (GDX)

P/E: 17.0 | Earnings yield: 5.9% | 52w drawdown: -26.5%

The ETF trades at a 26.5% drawdown with a 5.9% earnings yield, positioning gold miners at a discount to the S&P 500 CAPE of 38.9 while offering direct exposure to the metal's safe-haven dynamics. The one-year trend coefficient of 0.0024 reflects stabilization after the decline.

ETF structure means investors own basket volatility without company-specific catalysts, and the lack of FCF yield or insider data removes two key filters for conviction. Elliott Management's public statement on Northern Star Resources signals activist pressure within the underlying holdings, introducing headline risk without control.

4. Gilead Sciences, Inc. (GILD)

P/E: 16.9 | Earnings yield: 5.9% | 52w drawdown: -20.8%

ROIC of 24.4% combines with a 78.8% gross margin and 6.1% free cash flow yield, framing one of the highest-return pharmaceutical platforms on the screen. Earnings yield of 5.9% at a 20.8% drawdown positions the stock below its normalized 10-year P/E of 33.5, compressing valuation against historical profitability.

Three executives added 283,785 net shares over six months, including CFO Andrew Dickinson buying in May and June. Insiders deployed capital at 53% buy proportion across transactions while the company announced positive Phase 3 results for Livdelzi in primary biliary cholangitis, expanding the revenue base beyond HIV and oncology franchises.

August 6 earnings consensus projects a $7.14 loss per share, reflecting one-time charges or accounting treatment that obscures underlying cash generation and introduces short-term headline volatility.

5. KLA Corporation (KLAC)

P/E: 7.2 | Earnings yield: 13.8% | 52w drawdown: -87.6%

The stock trades at 7.22× earnings with a 66.5% ROIC and 11.2% free cash flow yield, printing the highest return on invested capital in the semiconductor cohort while sitting at an 88% drawdown. Revenue growth of 23.9% year-over-year and a 60.9% gross margin frame operational momentum that the price does not reflect.

The 88% drawdown signals structural dislocation beyond normal cyclical correction, and the normalized 10-year P/E of 101.0 suggests the current earnings base may compress or revert. CEO Richard Wallace sold 7,602 shares in June, and the analyst target of $1,855 implies 627% upside, a figure that reflects either data error or a market belief that the company's earnings will collapse from current levels.

Jim Cramer publicly called the stock "too risky," and the post-split valuation debate introduces uncertainty around whether AI-driven demand will offset semiconductor capital equipment cyclicality. EV-to-EBITDA at 43.5 sits far above the screen average, compressing the margin of safety despite the earnings yield.